OrganonOGN -0.07%71 Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 10 warning signs investors should review. Among 292 Drug Manufacturers companies, Organon ranks worse than 342465.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Organon's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OGN vs AMRN, SCLX, MIRA: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Organon's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Organon's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Organon and its competitors. According to the industry distribution chart, Organon ranks #999999 out of 292 companies in the Drug Manufacturers industry.
Is Organon's Buyback Yield % too high?
Organon's current Buyback Yield % is 0.00. Based on the distribution chart, Organon ranks #999999 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Buyback Yield % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #999999 out of 292 companies for Buyback Yield %. This places Organon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Organon and its competitors. Organon's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.54 — trading 6.9% below its estimated fair value. The current Buyback Yield % is 0.00. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Organon (OGN), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.54 is trading 6.9% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Buyback Yield %: 0.00
GF Value™: $14.55 vs. price of $13.54 (6.9% below fair value)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
